Cullinan Therapeutics (CGEM) Projected to Release Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.7993) per share and revenue of $3.6670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.09. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Trading Down 1.5%

CGEM opened at $17.21 on Thursday. The stock has a 50-day moving average of $16.26 and a 200 day moving average of $14.51. Cullinan Therapeutics has a 12 month low of $5.68 and a 12 month high of $19.43. The firm has a market cap of $1.06 billion, a P/E ratio of -5.12 and a beta of -0.01.

Insider Activity at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $17.82, for a total transaction of $142,560.00. Following the completion of the sale, the insider directly owned 162,844 shares of the company’s stock, valued at approximately $2,901,880.08. This represents a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new stake in Cullinan Therapeutics during the first quarter valued at approximately $163,000. Jane Street Group LLC increased its position in shares of Cullinan Therapeutics by 145.9% during the first quarter. Jane Street Group LLC now owns 34,396 shares of the company’s stock worth $260,000 after purchasing an additional 109,413 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Cullinan Therapeutics during the 1st quarter valued at $618,000. Creative Planning lifted its holdings in shares of Cullinan Therapeutics by 222.2% during the 2nd quarter. Creative Planning now owns 41,723 shares of the company’s stock valued at $314,000 after purchasing an additional 28,773 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Cullinan Therapeutics by 122.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 97,069 shares of the company’s stock worth $731,000 after purchasing an additional 53,522 shares in the last quarter. Institutional investors own 86.31% of the company’s stock.

Analysts Set New Price Targets

CGEM has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Cullinan Therapeutics in a research note on Monday, June 8th. Wall Street Zen raised shares of Cullinan Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Wedbush restated an “outperform” rating and set a $37.00 target price on shares of Cullinan Therapeutics in a report on Thursday, June 11th. Finally, BTIG Research increased their target price on Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.